Sinco Pharmaceuticals Holdings Ltd.

As of June 30, 2025, Sinco Pharmaceuticals Holdings Ltd. carries a market capitalization of 363.89M, placing it among publicly traded companies globally. Its enterprise value stands at 358.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Sinco Pharmaceuticals Holdings Ltd. has 2.03B shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Sinco Pharmaceuticals Holdings Ltd. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025.

As of the close on October 23, 2026, Sinco Pharmaceuticals Holdings Ltd.'s stock has declined approximately 27.14% over the past 52 weeks. The 50-day moving average sits at 0.16, while the 200-day moving average is 0.18.

As of June 30, 2025, Sinco Pharmaceuticals Holdings Ltd. holds 254.90M in cash and equivalents against 249.72M in total debt, resulting in a net debt position of -12.06M. Total book value stands at 749.06M, with working capital of 213.50M providing operational flexibility.